In the eye of the stormBMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7568.570 (Published 14 September 2006) Cite this as: BMJ 2006;333:570
- Susan Mayor
It was just an ordinary day in the intensive care unit of a busy London teaching hospital last March when a phone call from a nearby privately owned clinical trials unit catapulted the staff—and the six young men who became their patients—into the international spotlight.
Suddenly Ganesh Suntharalingam, director of intensive care at Northwick Park and St Mark's Hospital, London, and his team had to mount a rescue operation for six patients who simultaneously became seriously ill with a previously unknown reaction after taking a new type of drug. Neither he nor his two intensive care consultant colleagues, Andrew Castello-Cortes and Michael Brunner, were to get any sleep for the next 36 hours.
The healthy volunteers had each been given the new agent TGN1412, a superagonist anti-CD28 monoclonal antibody, which was designed to stimulate T cells, in the trial at a privately owned clinical trials …